Serum Calprotectin Level in Children: Marker of Obesity and its Metabolic Complications

Valeria Calcaterra, Mara De Amici, Maureen M Leonard, Annalisa De Silvestri, Gloria Pelizzo, Nicoletta Buttari, Alexandre Michev, Miriana Leggio, Daniela Larizza, Hellas Cena

Research output: Contribution to journalArticle

Abstract

AIM: Elevated calprotectin levels have been reported in obese adults but have not been evaluated in pediatric population. We investigated the characteristics of serum calprotectin in overweight and obese children and its association with metabolic comorbidities.

METHODS: We enrolled 131 children (11.7 ± 4.1 years). According to body mass index (BMI), the subjects were divided into 3 groups: obese > 95th percentile; overweight BMI 75th-95th percentile, and normal weight BMI < 75th percentile. Patients were classified as having Metabolic Syndrome if they met 3 or more of the following criteria for age and sex: BMI > 97th percentile, triglycerides > 95th percentile, high-density lipoprotein cholesterol < 5th percentile, systolic and/or diastolic blood pressure > 95th percentile, and impaired glucose tolerance. In all patients, calprotectin serum levels were also detected.

RESULTS: Calprotectin was higher in obese and overweight children than normal weight subjects (p < 0.001), with calprotectin in females being significantly higher than in males (p = 0.04). Increased calprotectin was related to pathological fasting blood glucose (p < 0.001) and insulin resistance (p = 0.03), while BMI (p = 0.001), and diastolic pressure (p = 0.001) are independent factors for increased calprotectin.

CONCLUSIONS: Our findings confirm the association between increased calprotectin and obesity also in children and suggest the potential utility of this biomarker in the monitoring of its metabolic complications.

Original languageEnglish
Pages (from-to)177-183
Number of pages7
JournalAnnals of Nutrition and Metabolism
Volume73
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Leukocyte L1 Antigen Complex
Pediatric Obesity
Serum
Body Mass Index
Weights and Measures
Glucose Intolerance
HDL Cholesterol
Insulin Resistance
Blood Glucose
Comorbidity
Fasting
Triglycerides
Obesity
Biomarkers
Pediatrics
Blood Pressure

Cite this

Serum Calprotectin Level in Children : Marker of Obesity and its Metabolic Complications. / Calcaterra, Valeria; De Amici, Mara; Leonard, Maureen M; De Silvestri, Annalisa; Pelizzo, Gloria; Buttari, Nicoletta; Michev, Alexandre; Leggio, Miriana; Larizza, Daniela; Cena, Hellas.

In: Annals of Nutrition and Metabolism, Vol. 73, No. 3, 2018, p. 177-183.

Research output: Contribution to journalArticle

@article{b9f04dd9e8ea4587aad63b1d2fe3feac,
title = "Serum Calprotectin Level in Children: Marker of Obesity and its Metabolic Complications",
abstract = "AIM: Elevated calprotectin levels have been reported in obese adults but have not been evaluated in pediatric population. We investigated the characteristics of serum calprotectin in overweight and obese children and its association with metabolic comorbidities.METHODS: We enrolled 131 children (11.7 ± 4.1 years). According to body mass index (BMI), the subjects were divided into 3 groups: obese > 95th percentile; overweight BMI 75th-95th percentile, and normal weight BMI < 75th percentile. Patients were classified as having Metabolic Syndrome if they met 3 or more of the following criteria for age and sex: BMI > 97th percentile, triglycerides > 95th percentile, high-density lipoprotein cholesterol < 5th percentile, systolic and/or diastolic blood pressure > 95th percentile, and impaired glucose tolerance. In all patients, calprotectin serum levels were also detected.RESULTS: Calprotectin was higher in obese and overweight children than normal weight subjects (p < 0.001), with calprotectin in females being significantly higher than in males (p = 0.04). Increased calprotectin was related to pathological fasting blood glucose (p < 0.001) and insulin resistance (p = 0.03), while BMI (p = 0.001), and diastolic pressure (p = 0.001) are independent factors for increased calprotectin.CONCLUSIONS: Our findings confirm the association between increased calprotectin and obesity also in children and suggest the potential utility of this biomarker in the monitoring of its metabolic complications.",
author = "Valeria Calcaterra and {De Amici}, Mara and Leonard, {Maureen M} and {De Silvestri}, Annalisa and Gloria Pelizzo and Nicoletta Buttari and Alexandre Michev and Miriana Leggio and Daniela Larizza and Hellas Cena",
note = "{\circledC} 2018 S. Karger AG, Basel.",
year = "2018",
doi = "10.1159/000492579",
language = "English",
volume = "73",
pages = "177--183",
journal = "Annals of Nutrition and Metabolism",
issn = "0250-6807",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Serum Calprotectin Level in Children

T2 - Marker of Obesity and its Metabolic Complications

AU - Calcaterra, Valeria

AU - De Amici, Mara

AU - Leonard, Maureen M

AU - De Silvestri, Annalisa

AU - Pelizzo, Gloria

AU - Buttari, Nicoletta

AU - Michev, Alexandre

AU - Leggio, Miriana

AU - Larizza, Daniela

AU - Cena, Hellas

N1 - © 2018 S. Karger AG, Basel.

PY - 2018

Y1 - 2018

N2 - AIM: Elevated calprotectin levels have been reported in obese adults but have not been evaluated in pediatric population. We investigated the characteristics of serum calprotectin in overweight and obese children and its association with metabolic comorbidities.METHODS: We enrolled 131 children (11.7 ± 4.1 years). According to body mass index (BMI), the subjects were divided into 3 groups: obese > 95th percentile; overweight BMI 75th-95th percentile, and normal weight BMI < 75th percentile. Patients were classified as having Metabolic Syndrome if they met 3 or more of the following criteria for age and sex: BMI > 97th percentile, triglycerides > 95th percentile, high-density lipoprotein cholesterol < 5th percentile, systolic and/or diastolic blood pressure > 95th percentile, and impaired glucose tolerance. In all patients, calprotectin serum levels were also detected.RESULTS: Calprotectin was higher in obese and overweight children than normal weight subjects (p < 0.001), with calprotectin in females being significantly higher than in males (p = 0.04). Increased calprotectin was related to pathological fasting blood glucose (p < 0.001) and insulin resistance (p = 0.03), while BMI (p = 0.001), and diastolic pressure (p = 0.001) are independent factors for increased calprotectin.CONCLUSIONS: Our findings confirm the association between increased calprotectin and obesity also in children and suggest the potential utility of this biomarker in the monitoring of its metabolic complications.

AB - AIM: Elevated calprotectin levels have been reported in obese adults but have not been evaluated in pediatric population. We investigated the characteristics of serum calprotectin in overweight and obese children and its association with metabolic comorbidities.METHODS: We enrolled 131 children (11.7 ± 4.1 years). According to body mass index (BMI), the subjects were divided into 3 groups: obese > 95th percentile; overweight BMI 75th-95th percentile, and normal weight BMI < 75th percentile. Patients were classified as having Metabolic Syndrome if they met 3 or more of the following criteria for age and sex: BMI > 97th percentile, triglycerides > 95th percentile, high-density lipoprotein cholesterol < 5th percentile, systolic and/or diastolic blood pressure > 95th percentile, and impaired glucose tolerance. In all patients, calprotectin serum levels were also detected.RESULTS: Calprotectin was higher in obese and overweight children than normal weight subjects (p < 0.001), with calprotectin in females being significantly higher than in males (p = 0.04). Increased calprotectin was related to pathological fasting blood glucose (p < 0.001) and insulin resistance (p = 0.03), while BMI (p = 0.001), and diastolic pressure (p = 0.001) are independent factors for increased calprotectin.CONCLUSIONS: Our findings confirm the association between increased calprotectin and obesity also in children and suggest the potential utility of this biomarker in the monitoring of its metabolic complications.

U2 - 10.1159/000492579

DO - 10.1159/000492579

M3 - Article

C2 - 30189427

VL - 73

SP - 177

EP - 183

JO - Annals of Nutrition and Metabolism

JF - Annals of Nutrition and Metabolism

SN - 0250-6807

IS - 3

ER -